232 related articles for article (PubMed ID: 29879685)
1. Cost-utility analysis of searching electronic health records and cascade testing to identify and diagnose familial hypercholesterolaemia in England and Wales.
Crosland P; Maconachie R; Buckner S; McGuire H; Humphries SE; Qureshi N
Atherosclerosis; 2018 Aug; 275():80-87. PubMed ID: 29879685
[TBL] [Abstract][Full Text] [Related]
2. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies.
Nherera L; Marks D; Minhas R; Thorogood M; Humphries SE
Heart; 2011 Jul; 97(14):1175-81. PubMed ID: 21685482
[TBL] [Abstract][Full Text] [Related]
3. Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.
McKay AJ; Hogan H; Humphries SE; Marks D; Ray KK; Miners A
Atherosclerosis; 2018 Aug; 275():434-443. PubMed ID: 29937236
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales.
Haralambos K; Whatley SD; Edwards R; Gingell R; Townsend D; Ashfield-Watt P; Lansberg P; Datta DB; McDowell IF
Atherosclerosis; 2015 May; 240(1):190-6. PubMed ID: 25797312
[TBL] [Abstract][Full Text] [Related]
5. Alternative cascade-testing protocols for identifying and managing patients with familial hypercholesterolaemia: systematic reviews, qualitative study and cost-effectiveness analysis.
Qureshi N; Woods B; Neves de Faria R; Saramago Goncalves P; Cox E; Leonardi Bee J; Condon L; Weng S; Akyea RK; Iyen B; Roderick P; Humphries SE; Rowlands W; Watson M; Haralambos K; Kenny R; Datta D; Miedzybrodzka Z; Byrne C; Kai J
Health Technol Assess; 2023 Oct; 27(16):1-140. PubMed ID: 37924278
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland.
Pelczarska A; Jakubczyk M; Jakubiak-Lasocka J; Banach M; Myśliwiec M; Gruchała M; Niewada M
Atherosclerosis; 2018 Mar; 270():132-138. PubMed ID: 29407882
[TBL] [Abstract][Full Text] [Related]
7. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.
Sharma P; Boyers D; Boachie C; Stewart F; Miedzybrodzka Z; Simpson W; Kilonzo M; McNamee P; Mowatt G
Health Technol Assess; 2012; 16(17):1-266. PubMed ID: 22469073
[TBL] [Abstract][Full Text] [Related]
8. Genetic diagnosis of familial hypercholesterolaemia using a rapid biochip array assay for 40 common LDLR, APOB and PCSK9 mutations.
Martin R; Latten M; Hart P; Murray H; Bailie DA; Crockard M; Lamont J; Fitzgerald P; Graham CA
Atherosclerosis; 2016 Nov; 254():8-13. PubMed ID: 27680772
[TBL] [Abstract][Full Text] [Related]
9. Genetically Confirmed Familial Hypercholesterolemia in Patients With Acute Coronary Syndrome.
Amor-Salamanca A; Castillo S; Gonzalez-Vioque E; Dominguez F; Quintana L; Lluís-Ganella C; Escudier JM; Ortega J; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
J Am Coll Cardiol; 2017 Oct; 70(14):1732-1740. PubMed ID: 28958330
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of cascade testing for familial hypercholesterolaemia, based on data from familial hypercholesterolaemia services in the UK.
Kerr M; Pears R; Miedzybrodzka Z; Haralambos K; Cather M; Watson M; Humphries SE
Eur Heart J; 2017 Jun; 38(23):1832-1839. PubMed ID: 28387827
[TBL] [Abstract][Full Text] [Related]
11. Genetic Testing for Familial Hypercholesterolemia: Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2022; 22(3):1-155. PubMed ID: 36158868
[TBL] [Abstract][Full Text] [Related]
12. Improving the Detection of Potential Cases of Familial Hypercholesterolemia: Could Machine Learning Be Part of the Solution?
Stevens CAT; Vallejo-Vaz AJ; Chora JR; Barkas F; Brandts J; Mahani A; Abar L; Sharabiani MTA; Ray KK
J Am Heart Assoc; 2024 Jun; 13(12):e034434. PubMed ID: 38879446
[TBL] [Abstract][Full Text] [Related]
13. A Comparative Analysis of Phenotypic Predictors of Mutations in Familial Hypercholesterolemia.
Chan DC; Pang J; Hooper AJ; Bell DA; Bates TR; Burnett JR; Watts GF
J Clin Endocrinol Metab; 2018 Apr; 103(4):1704-1714. PubMed ID: 29408959
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel LDLR disease-causing variant using capture-based next-generation sequencing screening of familial hypercholesterolemia patients in Taiwan.
Hsiung YC; Lin PC; Chen CS; Tung YC; Yang WS; Chen PL; Su TC
Atherosclerosis; 2018 Oct; 277():440-447. PubMed ID: 30270083
[TBL] [Abstract][Full Text] [Related]
15. Founder effects facilitate the use of a genotyping-based approach to molecular diagnosis in Swedish patients with familial hypercholesterolaemia.
Benedek P; Jiao H; Duvefelt K; Skoog T; Linde M; Kiviluoma P; Kere J; Eriksson M; Angelin B
J Intern Med; 2021 Aug; 290(2):404-415. PubMed ID: 33955087
[TBL] [Abstract][Full Text] [Related]
16. Developing and Optimizing Innovative Tools to Address Familial Hypercholesterolemia Underdiagnosis: Identification Methods, Patient Activation, and Cascade Testing for Familial Hypercholesterolemia.
Campbell-Salome G; Jones LK; Masnick MF; Walton NA; Ahmed CD; Buchanan AH; Brangan A; Esplin ED; Kann DG; Ladd IG; Kelly MA; Kindt I; Kirchner HL; McGowan MP; McMinn MN; Morales A; Myers KD; Oetjens MT; Rahm AK; Schmidlen TJ; Sheldon A; Simmons E; Snir M; Strande NT; Walters NL; Wilemon K; Williams MS; Gidding SS; Sturm AC
Circ Genom Precis Med; 2021 Feb; 14(1):e003120. PubMed ID: 33480803
[TBL] [Abstract][Full Text] [Related]
17. Screening for familial hypercholesterolaemia in primary care: Time for general practice to play its part.
Brett T; Qureshi N; Gidding S; Watts GF
Atherosclerosis; 2018 Oct; 277():399-406. PubMed ID: 30270077
[TBL] [Abstract][Full Text] [Related]
18. Homozygous familial hypercholesterolaemia in Vietnam: Case series, genetics and cascade testing of families.
Truong TH; Kim NT; Nguyen MNT; Pang J; Hooper AJ; Watts GF; Do DL
Atherosclerosis; 2018 Oct; 277():392-398. PubMed ID: 30270076
[TBL] [Abstract][Full Text] [Related]
19. DIAgnosis and Management Of familial hypercholesterolemia in a Nationwide Design (DIAMOND-FH): Prevalence in Switzerland, clinical characteristics and the diagnostic value of clinical scores.
Miserez AR; Martin FJ; Spirk D
Atherosclerosis; 2018 Oct; 277():282-288. PubMed ID: 30270060
[TBL] [Abstract][Full Text] [Related]
20. Widening the spectrum of genetic testing in familial hypercholesterolaemia: Will it translate into better patient and population outcomes?
Page MM; Bell DA; Watts GF
Clin Genet; 2020 Apr; 97(4):543-555. PubMed ID: 31833051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
